InvestorsHub Logo
Followers 14
Posts 817
Boards Moderated 0
Alias Born 02/24/2010

Re: Ernesto post# 121122

Tuesday, 09/08/2015 2:31:37 PM

Tuesday, September 08, 2015 2:31:37 PM

Post# of 403754
It doesn't matter to me if its 450 or 750. Orphan drug status came with 450 or less as did disappearing lesions. Wait till they start dosing for efficacy in phase 2. I don't agree with your time line for Kevetrin partnership. The details coming out of this phase 1 will start to trickle out of Harvard this year. I give equal weight to partnerships for Kevetrin solid tumors and Brilacidin ABX.